David R Matthews Selected Research

Canagliflozin

1/2022	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
12/2021	Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis.
1/2021	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.
1/2021	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
11/2020	Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
1/2020	Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
1/2020	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
1/2020	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
11/2019	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
10/2019	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David R Matthews Research Topics

Disease

50	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2004
18	Body Weight (Weight, Body) 01/2022 - 06/2004
11	Heart Failure 01/2022 - 10/2005
7	Stroke (Strokes) 01/2022 - 01/2018
7	Myocardial Infarction 01/2022 - 10/2008
7	Cardiovascular Diseases (Cardiovascular Disease) 11/2020 - 09/2015
6	Nausea 01/2022 - 01/2009
6	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2020 - 11/2004
5	Hypoglycemia (Reactive Hypoglycemia) 01/2018 - 06/2004
4	Vomiting 01/2022 - 03/2012
4	Albuminuria 01/2020 - 01/2017
3	Infections 12/2021 - 09/2015
3	Weight Gain 01/2018 - 06/2004
3	Insulin Resistance 08/2013 - 06/2004
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022 - 01/2021
2	Overweight 01/2022 - 10/2008
2	Diabetes Complications 10/2021 - 01/2021
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2021 - 01/2021
2	Genetic Risk Score 10/2021 - 01/2021
2	Kidney Diseases (Kidney Disease) 01/2021 - 01/2021
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 01/2018
2	Hypertension (High Blood Pressure) 01/2019 - 11/2004
2	Vascular Diseases (Vascular Disease) 01/2016 - 10/2014
1	ST Elevation Myocardial Infarction 01/2022
1	Heart Diseases (Heart Disease) 12/2021
1	Nervous System Diseases (Neurological Disorders) 12/2021
1	Diarrhea 01/2020
1	Hypotension (Low Blood Pressure) 01/2020
1	COVID-19 01/2020
1	Pancreatitis 01/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2019
1	Ischemic Stroke 01/2019
1	Peripheral Vascular Diseases (Peripheral Vascular Disease) 01/2019
1	Transient Ischemic Attack 01/2019
1	Retinal Detachment (Retinal Detachments) 01/2019
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2019
1	Hemorrhagic Stroke 01/2019
1	Chronic Renal Insufficiency 10/2018
1	Diabetes Mellitus 01/2018

Drug/Important Bio-Agent (IBA)

24	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 06/2004
21	CanagliflozinIBA 01/2022 - 09/2015
14	Insulin (Novolin)FDA Link 01/2022 - 06/2004
13	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 01/2004
9	SodiumIBA 01/2022 - 09/2015
7	Sodium-Glucose Transporter 2 InhibitorsIBA 04/2021 - 08/2013
6	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 06/2004
5	SymportersIBA 01/2022 - 09/2015
5	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2017
5	Liraglutide FDA Link 01/2021 - 06/2004
4	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 06/2004
4	AlbuminsIBA 01/2021 - 01/2018
4	CreatinineIBA 01/2021 - 01/2018
4	VildagliptinIBA 01/2021 - 04/2010
4	semaglutideIBA 01/2021 - 01/2018
4	Sodium-Glucose Transport ProteinsIBA 01/2020 - 08/2013
4	Pioglitazone (Actos)FDA Link 03/2012 - 01/2004
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 01/2018
3	Pharmaceutical PreparationsIBA 10/2018 - 06/2004
3	Gliclazide (Diamicron)IBA 01/2016 - 10/2005
3	glimepiride (Amarel)FDA LinkGeneric 04/2010 - 06/2004
2	Insulin Lispro (Humalog)FDA Link 10/2021 - 01/2018
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 04/2021 - 01/2019
2	dapagliflozinIBA 01/2021 - 08/2013
2	empagliflozinIBA 01/2021 - 01/2020
2	Exenatide (Byetta)FDA Link 01/2021 - 01/2021
2	HDL CholesterolIBA 01/2020 - 09/2019
2	CholesterolIBA 01/2020 - 09/2019
2	Hemoglobins (Hemoglobin)IBA 01/2020 - 01/2018
2	Triglycerides (Triacylglycerol)IBA 09/2019 - 05/2012
2	Retinaldehyde (Retinal)IBA 01/2019 - 01/2016
2	perindopril drug combination indapamideIBA 01/2016 - 10/2014
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 09/2015 - 10/2014
2	Glucagon (Glukagon)FDA Link 04/2010 - 06/2004
2	C-PeptideIBA 06/2004 - 06/2004
1	tirzepatideIBA 01/2022
1	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 01/2022
1	InsulinsIBA 10/2021
1	omega-Chloroacetophenone (Mace)IBA 04/2021
1	pramlintide (Symlin)FDA Link 01/2021
1	ertugliflozinIBA 01/2021
1	Lipoproteins (Lipoprotein)IBA 01/2020
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2020
1	Bicarbonates (Hydrogen Carbonate)IBA 01/2020
1	Serum AlbuminIBA 01/2020
1	Uric Acid (Urate)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	dulaglutideIBA 01/2020
1	LipidsIBA 09/2019
1	Apolipoproteins B (ApoB)IBA 09/2019
1	N 30IBA 01/2019
1	insulin degludecIBA 01/2018
1	Protamines (Protamine Sulfate)FDA Link 01/2018
1	Insulin Glargine (Lantus)FDA Link 01/2018

Therapy/Procedure

16	Therapeutics 01/2022 - 03/2003
6	Glycemic Control 01/2019 - 01/2004
5	Surgical Amputation (Amputations) 01/2020 - 01/2016
2	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2018 - 01/2017
2	Light Coagulation 01/2016 - 11/2004
1	Treatment Delay 01/2021
1	Secondary Prevention 01/2018